350 Epizód

  1. 326: Crypto for CRISPR, a new RNAi startup, & a Nobel for AI

    Közzétéve: 2024. 10. 10.

  2. 325: Biden's health care AI czar, a new obesity company, and its dealmaking CEO

    Közzétéve: 2024. 10. 03.

  3. From Tradeoffs: Race to the Bottom

    Közzétéve: 2024. 09. 28.

  4. 324: Genentech's cancer pivot, Pfizer's sickle cell withdrawal, and a new schizophrenia drug

    Közzétéve: 2024. 09. 26.

  5. 323: Cannabinoids for weight loss, a cancelled ad comm, and the Fed lowers interest rates

    Közzétéve: 2024. 09. 19.

  6. 322: A new threat to Merck's blockbuster cancer treatment, Moderna's cutbacks, and obesity drugs for kids

    Közzétéve: 2024. 09. 12.

  7. 321: Summit's upcoming cancer results, Recursion's mixed data, and the next big obesity target

    Közzétéve: 2024. 09. 05.

  8. 320: Jim Wilson's next venture, a surprise startup shutdown, & Lilly's Zepbound strategy

    Közzétéve: 2024. 08. 29.

  9. From "Say More": What Happens When AI Decides Your Medical Coverage

    Közzétéve: 2024. 08. 23.

  10. 319: BioMarin's executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion's AI bona fides

    Közzétéve: 2024. 08. 22.

  11. 318: Drug pricing drops & psychedelics under fire

    Közzétéve: 2024. 08. 15.

  12. 317: VC struggles, drug pricing negotiations, & Novo's abrupt Wegovy decision

    Közzétéve: 2024. 08. 08.

  13. 316: The long journey to make malaria vaccines, and Sarepta's ties with patient advocates

    Közzétéve: 2024. 08. 01.

  14. 315: UnitedHealth's doctor empire, an FDA departure, and Viking's obesity moves

    Közzétéve: 2024. 07. 25.

  15. 314: JD Vance's biotech ties, Cassava resignations, and insulin shortages

    Közzétéve: 2024. 07. 18.

  16. 313: Biotech layoffs, founder-focused VC, & a big pharma exit

    Közzétéve: 2024. 07. 11.

  17. 312: Medicare coverage for GLP-1 drugs, AI, and health care at the presidential debate

    Közzétéve: 2024. 06. 27.

  18. 311: Fauci's memoir, Alnylam's tenuous trial, and a mid-year review

    Közzétéve: 2024. 06. 20.

  19. 310: Duchenne gene therapy setback, Alzheimer's drug endorsement & why a STAT reporter buys weed (for journalism)

    Közzétéve: 2024. 06. 13.

  20. 309: Psychedelics at the FDA, ASCO recap, & MorphoSys update

    Közzétéve: 2024. 06. 06.

2 / 18

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

Visit the podcast's native language site